文献速递技术与安全PET

68Ga-DOTA.SA.FAPi 作为多种上皮性恶性肿瘤的多能诊断探针:与18F-FDG的头对头比较

68Ga-DOTA.SA.FAPi as a Versatile Diagnostic Probe for Various Epithelial Malignancies: A Head-to-Head Comparison with 18F-FDG.
PubMed 文献 · Acad Radiol · 2024-01-16

这项前瞻性研究纳入25例四种上皮性恶性肿瘤患者,比较68Ga-SA.FAPi与18F-FDG PET显像。68Ga-SA.FAPi在总体分析中SUVmax、SULpeak、SULavg显著高于18F-FDG,TBR相当;原发灶和远处转移灶摄取更高,淋巴结转移灶相当;在1例肾上腺皮质癌中额外检出5个18F-FDG漏诊的肺部病灶。

要点

  • 68Ga-SA.FAPi在多种上皮性恶性肿瘤中显示与18F-FDG相似或更高的病灶摄取。
  • 淋巴结转移灶两种示踪剂摄取相当,肺部结节和淋巴结检出存在不一致。
  • 68Ga-SA.FAPi可在个别病例中检出18F-FDG遗漏的肺部病灶。

核心结论

  • 68Ga-SA.FAPi是一种有效、多能的诊断探针,可用于多种上皮性恶性肿瘤的显像,效果与18F-FDG相似。

研究设计与样本

  • 前瞻性研究,纳入25例患者,在两天分别进行18F-FDG和68Ga-SA.FAPi PET扫描,通过勾画感兴趣区计算SUV进行生物分布和病灶比较分析。

关键影像表现/征象

  • 68Ga-SA.FAPi在唾液腺、甲状腺、肝脏、胰腺、肌肉和肾脏可见生理性摄取,在泪腺、眼外肌、口腔黏膜和子宫可见可变摄取。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: Fibroblast Activation Protein (FAP) expressing cancer-associated fibroblasts has been a major breakthrough causing a paradigm shift in targeted theranostics focusing on the tumor microenvironment. In this study, a squaric acid derivative DOTA.SA.FAPi (SA.FAPi) has been evaluated as a potential diagnostic probe in diverse epithelial cancers and compared to the standard-of-care 18F-FDG.

METHODS: 25 patients enrolled in this prospective study underwent 18F-FDG and 68Ga-SA.FAPi PET scans on two different days. For biodistribution, standardized uptake values (SUV) were computed by delineating region-of-interest on various body organs. For comparative analysis in disease identification, lesion tracer uptake was quantified using SUVs corrected for lean body mass (SUL), SUVmax, tumor-to-background ratio (TBR) with liver and blood pool as the reference, total lesion glycolysis (TLG for 18F-FDG) and total lesion FAP expression (TLF for 68Ga-SA.FAPi).

RESULTS: 25 patients (mean age: 58 ± 8 years) with four types of cancers including hepatocellular carcinoma (HCC, 56% of cohort), gall bladder carcinoma (GB Ca, 12%), adrenocortical carcinoma (ACC, 16%), and breast carcinoma (breast Ca, 16%) were prospectively evaluated. Physiological tracer uptake of 68Ga-SA.FAPi was noted in the salivary glands, thyroid, liver, pancreas, muscles and kidneys with variable uptake in the lacrimal glands, extra-ocular muscles, oral mucosa and uterus. Lesion-based comparative analysis between both the radiotracers demonstrated complete concordant findings in detection of all primary lesions and distant metastases in liver, bones, adrenals and peritoneum whereas discordant findings were noted in lung nodules (20%) and lymph nodes (13%). In overall analysis, 68Ga-SA.FAPi exhibited significantly higher SUVmax (10.3 vs 8.8, p-0.019), SULpeak (6.8 vs 4.9, p-0.000) and SULavg (5.4 vs 4.1, p-0.019) in comparison to 18F-FDG whereas TBR was comparable for both the tracers [TBRLiver: median 1.9 (IQR: 2.6-1.4) vs 1.8 (2.6-1.1), p-0.275; TBRBloodpool: 2.1 (3.7-1.4) vs 2.0 (2.7-1.4), p-0.207]. In subcategorical analysis, 68Ga-SA.FAPi demonstrated higher SUVmax, SULpeak and SULavg values for primary disease (SUVmax: 14.8 (18.7-9.7) vs (12.9-6.6), p-0.087; SULpeak: 8.2 (11.2-6.8) vs 6.3 (8.5-4.4), p-0.037; SULavg: 6.9 ± 2.5 vs 5.1 ± 2.2, p-0.023] and distant metastases (8.8 vs 7.2, p-0.038); 6.3 (8.8-4.4) vs 3.6 (4.4-2.0), p-0.000; 5.4 vs 3.5, p-0.000] whereas comparable values were noted for both the tracers in nodal metastases [9 (13.5-4.1) vs 8 (12.7-4.7), p-0.726; 4.5 (6.2-1.8) vs 4.3 (5.7-2.2), p-0.727; 4.1 ± 2.3 vs 3.7 ± 1.8, p-0.129]. In primary disease, highest 68Ga-SA.FAPi avidity was noted in ACC followed by GB Ca and HCC. In distant metastases, gall bladder, lung and skeletal lesions demonstrated higher 68Ga-SA.FAPi avidity. Moreover, 68Ga-SA.FAPi identified five additional lung lesions which were missed by 18F-FDG in one case of ACC.

CONCLUSION: 68Ga-SA.FAPi emerged as an effective, versatile diagnostic probe for imaging various epithelial malignancies similar to 18F-FDG.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Chopra S, Mathur Y, Roesch F, et al. 68Ga-DOTA.SA.FAPi as a Versatile Diagnostic Probe for Various Epithelial Malignancies: A Head-to-Head Comparison with 18F-FDG. Acad Radiol. 2024. PMID: 38233261. doi:10.1016/j.acra.2023.12.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。